Knights of Columbus Asset Advisors LLC Grows Position in Boston Scientific Corporation $BSX

Knights of Columbus Asset Advisors LLC grew its stake in Boston Scientific Corporation (NYSE:BSX) by 8.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 68,862 shares of the medical equipment provider’s stock after buying an additional 5,188 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Boston Scientific were worth $7,396,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BSX. Merit Financial Group LLC increased its position in shares of Boston Scientific by 12.0% in the 2nd quarter. Merit Financial Group LLC now owns 134,928 shares of the medical equipment provider’s stock valued at $14,493,000 after acquiring an additional 14,508 shares during the period. IVC Wealth Advisors LLC grew its stake in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares during the last quarter. Simplicity Wealth LLC raised its stake in shares of Boston Scientific by 97.0% in the second quarter. Simplicity Wealth LLC now owns 40,214 shares of the medical equipment provider’s stock worth $4,319,000 after purchasing an additional 19,800 shares during the last quarter. Penobscot Investment Management Company Inc. raised its stake in shares of Boston Scientific by 31.4% in the second quarter. Penobscot Investment Management Company Inc. now owns 42,607 shares of the medical equipment provider’s stock worth $4,576,000 after purchasing an additional 10,177 shares during the last quarter. Finally, AMF Tjanstepension AB acquired a new stake in shares of Boston Scientific during the second quarter worth about $95,402,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $97.30 on Monday. The firm has a market cap of $144.17 billion, a PE ratio of 57.91, a P/E/G ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business has a 50-day moving average price of $102.93 and a 200 day moving average price of $102.06.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday. Finally, UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $120.79.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 in the last quarter. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.